The trajectory of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial release generated substantial profits, the expiration of its patent opened the avenue to cheaper alternatives, dramatically eroding revenue. This creates a specific dilemma for firms relying on related blockbuster offerings, suggesting

The story of Viagra, and its creator copyright, presents a intriguing case study for investors. Originally a blockbuster drug, producing billions in income, its patent expiration created a flood of knock-off medications, significantly impacting its dominance. While specific businesses may seek to capitalize on related treatments , the existing land